Bret Jensen
Contributor since: 2010
Company: The Biotech Forum
Intra-Cellular Therapies: Key Catalyst On The Horizon
Spring Bank: An Interesting $5 Biotech Concern
MacroGenics: Updating The Investment Thesis
Catalent: Buy, Sell, Or Hold?
Dynavax: Circling The Wagons
The Investment Thesis On Acceleron Pharma
Flexion Therapeutics: The Bottom Could Now Be In
Peeking Back In On Portola Pharmaceuticals
BioDelivery's Bang Up Quarter
Myriad Genetics: Buy, Sell Or Hold?
The Prognosis For Ascendis Pharma
Our Take On XBiotech
Collegium Pharmaceuticals: Post-Q4 Assessment
Alpine Immune Sciences: A New Name On The Radar
Omeros: The Prognosis Brightens
Superlative Quarter For Supernus
Invitae Continues To Roll
Exelixis Does It Again
The Insiders' Edge With Bret Jensen (Podcast)
Global Blood Therapeutics: A Crucial Year Ahead
BioDelivery Sciences: The Momentum Continues To Build
AVEO Pharmaceuticals Gets Sideswiped
The Biotech M&A Landscape
Verastem: A Compelling Risk/Reward Profile
Alexion Pharmaceuticals: In The News And Moving Higher
The Verdict On Aerie Pharmaceuticals
Can Gene Editing Concerns Bounce Back?
An Update On Sage Therapeutics
2 Biotech Stocks On Watch Early In The Week
Aclaris Therapeutics: Buy, Sell Or Hold?
Dynavax Technologies: 2019 Looks Bright
Omeros: Key Inflection Point Achieved